Cost-utility of somatropin (rDNA origin) in the treatment of growth hormone deficiency in children

Current Medical Research and Opinion

Volumn 22, Issue 2, 2006, Pages 351-357

  Joshi, Ashish V ^a   Munro, Vicki ^b   Russell, Mason W ^c  

^a NOVO NORDISK INC   (United States)

^b Novo Nordisk Ltd   (United Kingdom)

^c Boston Health Economics Inc   (United States)

Author keywords

Cost effectiveness; Cost utility; Human growth hormone; QALY; Somatropin

Indexed keywords

HUMAN GROWTH HORMONE; RIBOSOME DNA; RECOMBINANT DNA;

ADOLESCENT; ADULT; ARTICLE; BODY HEIGHT; BODY WEIGHT; CHILD; COHORT ANALYSIS; CONSULTATION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DEMOGRAPHY; DOSE RESPONSE; DRUG COST; FEMALE; GROWTH HORMONE DEFICIENCY; HEALTH PRACTITIONER; HUMAN; MALE; MEDICAL ASSESSMENT; MEDICAL DECISION MAKING; MEDICAL LITERATURE; MULTIVARIATE ANALYSIS; PRIMARY MEDICAL CARE; PUBLICATION; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; UNIVARIATE ANALYSIS; COMPARATIVE STUDY; COST; ECONOMICS; GENETICS; PITUITARY DWARFISM; PRESCHOOL CHILD; UNITED KINGDOM;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; COSTS AND COST ANALYSIS; DNA, RECOMBINANT; DWARFISM, PITUITARY; FEMALE; GREAT BRITAIN; HUMAN GROWTH HORMONE; HUMANS; MALE; QUALITY-ADJUSTED LIFE YEARS;

EID: 33645741744     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X80503     Document Type: Article

References (12)

1. American Association of Clinical Endocrinologists. Medical guidelines for clinical practice for growth hormone use in adults and children - 2003 update. Endocr Pract 2003;9:65-76
2. Wit JM. Growth hormone therapy. Best Pract Res Clin Endocrinol Metab 2002;16:483-503
3. Lindsay R, Feldkamp M, Harris D, et al. Utah Growth Study: growth standards and the prevalence of growth hormone deficiency. J Pediatr 1994;125:29-35
4. US Department of Commerce, Bureau of the Census, Current population estimates 2005. Accessed at http://www.census.gov, 20 August 2005
5. Data on file, Novo Nordisk Inc., 2005
6. National Institute for Clinical Excellence, guidance on the use of human growth hormone (somatropin) in children with growth failure. Technology Appraisal No. 42, May 2002
7. Wessex Development and Education Committee (DEC). Growth hormone in children (for growth hormone deficiency, Turner's syndrome, chronic renal failure and idiopathic short stature). Bristol: Wessex Institute for Health Research and Development; 1996. Report No. 57
8. Rosser R, Cottee M, Rabin R, et al. Index of health-related quality of life. In: Hopkins A, editor. Measures of the quality of life. London: Royal College of Physicians; 1992
9. Drug topics red book (update). Thomson Healthcare, March 2005
10. Medicare physician fee schedule payment amount file. Baltimore (MD): Centers for Medicare and Medicaid Services, US Department of Health and Human Services, January 2005. Accessed at http://www.cms.hhs.gov/providers/ pufdownload/default.asp#pfspayment, 20 August 2005
11. Ogden CL, Fryar CD, Carroll MD, et al. Mean body weight, height, and body mass index, United States 1960-2002. Advance data from vital and health statistics; No. 347. Hyattsville (MD): National Center for Health Statistics; 2004
12. Bryant J, Cave C, Mihaylova B, et al. Clinical effectiveness and cost-effectiveness of growth hormone in children: a systematic review and economic evaluation. Health Technol Assess 2002;6:18-20